Literature DB >> 18424279

Clinical utility of type 1 growth factor receptor expression in colon cancer.

Sher-Ping Leung1, Obi L Griffith, Hamid Masoudi, Allen Gown, Steven Jones, Terry Phang, Sam M Wiseman.   

Abstract

BACKGROUND: To evaluate the expression pattern and prognostic significance of the type 1 growth factor receptor (T1GFR) family in colon carcinoma.
METHODS: Tissue microarrays were constructed using 127 tumor samples and 47 metastatic lymph nodes and T1GFR family expression was determined by immunohistochemistry. Univariate and multivariate analyses examined clinicopathologic variables for prognostic significance, and the correlation between primary and lymph node expression was determined by Spearman correlation.
RESULTS: Overexpression of HER-1, HER-2, HER-3, and HER-4 in tumor samples was 32%, 1%, 12%, and 37%, respectively, and 30%, 0%, 11%, and 24% in nodal samples, respectively. On multivariate analysis, positive margins, lymphatic invasion, and HER-3 expression were significant predictors of survival outcome. There was significant correlation between tumor and regional lymph node expression for the T1GFR family members. Tumor HER-3 expression was associated with lymphatic invasion and distant recurrence.
CONCLUSIONS: Tumor HER-3 expression has prognostic utility in individuals with colon carcinoma. Correlation between tumor and lymph node expression of T1GFR family members suggests that tumor receptor status may guide targeted therapy selection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424279     DOI: 10.1016/j.amjsurg.2007.12.032

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  TNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival.

Authors:  Valda C Hilliard; Mark R Frey; Peter J Dempsey; Richard M Peek; D Brent Polk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-26       Impact factor: 4.052

2.  The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

Authors:  Mario Scartozzi; Alessandra Mandolesi; Riccardo Giampieri; Alessandro Bittoni; Chiara Pierantoni; Alberto Zaniboni; Eva Galizia; Lucio Giustini; Rosa Rita Silva; Renato Bisonni; Rossana Berardi; Tommasina Biscotti; Simona Biagetti; Italo Bearzi; Stefano Cascinu
Journal:  Oncologist       Date:  2011-01-06

3.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

Authors:  Christopher S Williams; Jessica K Bernard; Michelle Demory Beckler; Dana Almohazey; Mary Kay Washington; Jesse J Smith; Mark R Frey
Journal:  Carcinogenesis       Date:  2015-04-27       Impact factor: 4.944

4.  ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.

Authors:  Mark R Frey; Valda C Hilliard; Matthew T Mullane; D Brent Polk
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

5.  Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.

Authors:  Sadaf Farzand; Tahir Siddique; Kanwal Saba; Mulazim Hussain Bukhari
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

6.  Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.

Authors:  Said Abdullah Khelwatty; Sharadah Essapen; Izhar Bagwan; Margaret Green; Alan Michael Seddon; Helmout Modjtahedi
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  ErbB receptors and their growth factor ligands in pediatric intestinal inflammation.

Authors:  Mark R Frey; D Brent Polk
Journal:  Pediatr Res       Date:  2013-11-06       Impact factor: 3.756

8.  Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.

Authors:  Anna H Larsson; Sophie Lehn; Sakarias Wangefjord; Emelie Karnevi; Eugenia Kuteeva; Magnus Sundström; Björn Nodin; Mathias Uhlén; Jakob Eberhard; Helgi Birgisson; Karin Jirström
Journal:  J Transl Med       Date:  2016-05-10       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.